Ascletis Pharma Inc.

Investors

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
2025-10-20
Next Day Disclosure Returns - Share Buyback
2025-10-17
Next Day Disclosure Returns - Share Buyback
2025-10-15
Voluntary Announcement - Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
2025-10-14
Next Day Disclosure Returns - Share Buyback
2025-10-13
Voluntary Announcement - Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
2025-10-13
Next Day Disclosure Returns - Share Buyback
2025-10-10
Next Day Disclosure Returns - Share Buyback
2025-10-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
2025-10-03
Next Day Disclosure Returns - Share Buyback
2025-10-02

2

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1